Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Cost-effectiveness
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Mediastinoscopy
100%
Outcome Efficacy
100%
Staged Strategy
100%
Life-years Gained
50%
Incremental Cost-effectiveness Ratio
37%
Quality-adjusted Life Years
37%
Tumor
25%
Quality-adjusted Life Expectancy
25%
T Classification
25%
Diagnostic Test
12%
Health Outcomes
12%
Medical Technology
12%
Optimal Strategy
12%
Decision-analytic Model
12%
Risk-benefit
12%
Risk Cost
12%
Societal Perspective
12%
Probability Estimates
12%
Health Costs
12%
Model Estimates
12%
Overall Cost
12%
N3 Disease
12%
Overall Effectiveness
12%
Mediastinal Involvement
12%
Combined Modality Therapy
12%
Multimodal Regimen
12%
Suvival
12%
Diagnostic Intervention
12%
Chest Computed Tomography
12%
Cost per Quality-adjusted Life Year
12%
Medicine and Dentistry
Health Care Cost
100%
Non Small Cell Lung Cancer
100%
Mediastinoscopy
100%
Quality Adjusted Life Year
50%
Cost Effectiveness Analysis
37%
Life Expectancy
25%
Neoplasm
12%
Health Outcomes
12%
Computer Assisted Tomography
12%
Medical Technology
12%
Mediastinum
12%
Tumor
12%
Diseases
12%
Diagnostic Test
12%